UNSPSC 51282503: Cefalexin or cephalexin

This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OBN7UDS42Y. European Medicines Agency schedules Cefalexin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06165MIG. Cefalexin generally arises in the molecular formula C16H17N3O4S. The term CEFALEXIN is an International Non-Proprietary Name or INN. CEFALEXIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Cefalexin or cephalexin bears US NLM identifiers UMLS ID C0007716 and NCI Concept Code C356. SMILES: S1C2N(C(=O)C2NC(=O)C(N)C2CCCCC2)C(=C(C1)C)C(=O)O.

UNSPSC 51282503 Cefalexin or cephalexin is a Commodity code that nominally names a single antibiotic product, but recent state and local solicitations show minimal alignment with this specific pharmaceutical. The code's recent activity reflects a mismatch between its abstract scope and what state and local governments are actually procuring — the recent opportunities instead target broad pharmaceutical procurement vehicles, medical supply frameworks, and drug-management initiatives rather than cefalexin specifically. State and local issuing bodies soliciting under this code span county health departments, state pharmacy benefit agencies, and municipal fire-rescue operations, with activity concentrated in Florida, Texas, and Minnesota. The work being acquired includes naloxone and drug-deactivation systems for community health initiatives, direct-to-manufacturer prescription programs, medical and first-aid supplies for emergency response, and generic pharmaceutical products through cooperative purchasing frameworks.

Recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug-deactivation systems annually (posted June 30, 2026, response due July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first-aid supplies for the Fire Department Rescue Division with an estimated contract amount of $700,000 and SLBE set-aside designation (posted March 25, 2026, response due March 13, 2026), the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs (posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson (posted January 20, 2026, response due March 26, 2026). This code shows limited relevant recent activity specifically targeting cefalexin; the tagged opportunities reflect broader pharmaceutical procurement strategies where specific antibiotics may appear as line items within larger medical-supply or pharmacy-benefit contracts.